News | February 13, 2026
Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
The revenues this quarter are in line with the outlook we envisaged for the year
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
Subscribe To Our Newsletter & Stay Updated
